Analysis of a New Biomarker for Prostate Cancer Diagnosis

Patients With Suspected Prostate Cancer Clinical Trial

— HEM  

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT01819740
• Other study ID #: CSPT/URO/2013/PROSTATE
• Status: Not yet recruiting
• Phase: N/A
• First received: March 25, 2013
• Last updated: March 27, 2013
• Start date: April 2013

Study information

• Verified date: March 2013
• Source: Corporacion Parc Tauli
• Contact: Miriam Barrio-Muñoz
• Phone: 34 93 723 10 10
• Email: mbarrio6[@]gmail.com
• Is FDA regulated: No
• Health authority: Spain: Comité Ético de Investigación Clínica
• Study type: Observational

Clinical Trial Summary

The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 28
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinical or laboratory suspected of prostate cancer

Exclusion Criteria:

• Inability to ejaculate

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

• Patients With Suspected Prostate Cancer
• Prostatic Neoplasms

Intervention

Other:
• determine the levels of the "HEM" substance in seminal plasma

Locations

Country	Name	City	State
Spain	Hospital Universitario Parc Taulí	Sabadell	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry		1 hour	Yes